6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4) has been identified to enhance the chemoresistance in small-cell lung cancer (SCLC) and is an indicative of poor therapeutic response and prognosis in this disease [20]. The gene discussed is PFKFB4; the disease is small cell lung carcinoma.